Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

BioSante to Resume Prostate Cancer Vaccine Testing

By Pharmaceutical Processing | May 3, 2010

LINCOLNSHIRE, Ill. (AP) — BioSante Pharmaceuticals Inc. said Monday it hopes to restart testing of an experimental prostate cancer drug almost two years after the research was stopped.

BioSante said it will resume testing of its GVAX drug by year-end, subject to regulatory approval. The company that initially developed the vaccine, Cell Genesys, put a trial of the drug on hold in August 2008 because of a high number of deaths among patients taking the drug. Regulators then placed a halt on another study. BioSante bought Cell Genesys last October and is testing GVAX as a treatment for leukemia and pancreatic cancer.

The move comes only days after the Food and Drug Administration approved Dendreon Corp.’s prostate cancer drug Provenge. Both Provenge and GVAX are sometimes called vaccines because they are designed to train a patient’s immune system to fight cancer. However, they are therapies and not preventive treatments.

BioSante said it has started manufacturing new GVAX Prostate and is working to get the Food and Drug Administration to allow it to resume testing. It hopes to begin treating patients in a midstage clinical study in the beginning of the fourth quarter.

In morning trading, BioSante stock rose 14 cents, or 6 percent, to $2.49.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE